Richard Pietras to Drug Resistance, Neoplasm
This is a "connection" page, showing publications Richard Pietras has written about Drug Resistance, Neoplasm.
Connection Strength
0.744
-
Hurvitz SA, Pietras RJ. Rational management of endocrine resistance in breast cancer: a comprehensive review of estrogen receptor biology, treatment options, and future directions. Cancer. 2008 Nov 01; 113(9):2385-97.
Score: 0.294
-
Dowsett M, Nicholson RI, Pietras RJ. Biological characteristics of the pure antiestrogen fulvestrant: overcoming endocrine resistance. Breast Cancer Res Treat. 2005; 93 Suppl 1:S11-8.
Score: 0.225
-
Deng X, Apple S, Zhao H, Song J, Lee M, Luo W, Wu X, Chung D, Pietras RJ, Chang HR. CD24 Expression and differential resistance to chemotherapy in triple-negative breast cancer. Oncotarget. 2017 Jun 13; 8(24):38294-38308.
Score: 0.134
-
Weinberg OK, Marquez-Garban DC, Pietras RJ. New approaches to reverse resistance to hormonal therapy in human breast cancer. Drug Resist Updat. 2005 Aug; 8(4):219-33.
Score: 0.059
-
Wu Y, Tran T, Dwabe S, Sarkissyan M, Kim J, Nava M, Clayton S, Pietras R, Farias-Eisner R, Vadgama JV. A83-01 inhibits TGF-?-induced upregulation of Wnt3 and epithelial to mesenchymal transition in HER2-overexpressing breast cancer cells. Breast Cancer Res Treat. 2017 Jun; 163(3):449-460.
Score: 0.033